Back
HFA Premium Access

Dose reduction and contraindication of the novel oral anticoagulant in patients with heart failure and reduced ejection fraction during a follow-up of 27 month. Data from CORONA Trial

Session: Poster Session 2 - Drug therapy, other
Topic: Drug therapy, other
Speaker: Doctor A. Pozzi (Como, IT)
Event: HEART FAILURE 2016

Congress Presentation

Add to my library

Like

About the speaker

Doctor Andrea Pozzi

Hospital Valduce, Como (Italy)
0 follower

9 more presentations in this session

Efficacy of trimetazidine on functional capacity in symptomatic patients with moderately reduced or left ventricular dysfunction and CAD: a subgroup analysis of the VASCO trial

Access
Like
Thumbnail

Pharmacological treatment of chronic heart failure during cardiac resynchronization therapy

Speaker: Doctor J. Laukaitiene (Kaunas, LT)

Access
Abstract
Slides
Like
Thumbnail

Effect of levosimendan on left and right ventricular function in patients with acute and chronic heart failure: a review of echocardiographic studies

Speaker: Associate Professor M. Cameli (Siena, IT)

Access
Abstract
Like
Thumbnail

Two drugs comparasion of bisoprolol in efficiency influence on the heart rate from a position of pharmacoeconomics

Access
Like
Thumbnail

How many patients with chronic heart failure will be eligible for LCZ696 in the community?

Speaker: Doctor P. Pellicori (Glasgow, GB)

Access
Abstract
Like
Thumbnail

Access the full session

Poster Session 2 - Drug therapy, other

Speakers: Doctor A. Pozzi, Doctor J. Laukaitiene, Associate Professor M. Cameli, Doctor P. Pellicori
Access
Like
Thumbnail

About the event

Image

HEART FAILURE 2016

21 May - 24 May 2016

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources